Jill Weimer is Chief Science Officer at Amicus Therapeutics & Senior Director of Therapeutic Development at Sanford Research, where she studies the processes that control development in the cerebral cortex and how disruptions in these processes lead to various neuropediatric diseases. A developmental neuroscientist, she earned her B.S. and Ph.D. in neuroscience from the University of Rochester and completed postdoctoral training at the University of North Carolina at Chapel Hill. Before joining Amicus, Dr. Weimer served as Senior Director of Therapeutic Development in the Pediatrics and Rare Diseases group at Sanford Research and held academic appointments at the University of South Dakota. Her laboratory pioneered early gene therapy programs for rare neurodegenerative disorders, including CLN3 and CLN6 forms of Batten disease. At Amicus, she leads scientific strategy and therapeutic development for rare genetic conditions, with a continued focus on innovation and translational research. Dr. Weimer also advises scientific foundations and serves on academic and industry councils supporting the advancement of rare disease research and patient-centered therapeutic development.